MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

166.23 -0.57 (-0.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Neurocrine (NBIX) Q2 2026 Earnings Call Transcript ↗
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%. 
Via The Motley Fool
Topics Earnings
News headline image
Neurocrine Biosciences Q2 Earnings Call Highlights ↗
Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the... 
Via MarketBeat
Topics Earnings
News headline image
Neurocrine (NBIX) Q2 2026 Earnings Call Transcript ↗
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%. 
Via The Motley Fool
Topics Earnings
Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setup ↗
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Stock ↗
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Offers a High Growth Momentum Breakout Setup ↗
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screen ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setup ↗
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Framework ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Decent Value Play with Strong Fundamentals ↗
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategy ↗
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82 ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and Bull Flag Breakout Setup ↗
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Momentum Breakout Setup ↗
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Shows Affordable Growth Potential ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals ↗
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunity ↗
Via Chartmill
News headline image
Neurocrine (NBIX) Q1 2026 Earnings Transcript ↗
Neurocrine (NBIX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Neurocrine Biosciences (NASDAQ:NBIX) Smashes Q1 Estimates with 44% Sales Surge ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
Neurocrine Biosciences Inc (NASDAQ:NBIX) Qualifies for Affordable Growth Screen with Strong GARP Profile ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Leggett & Platt, Incorporated (NYSE – LEG), Soleno Therapeutics, Inc. (Nasdaq – SLNO), Forian, Inc. (Nasdaq – FORA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story